Our Personalized Weight Loss Consultation is not just about shedding pounds
Lipid Metabolism In the SURPASS and SURMOUNT phase 3 clinical trial programs (Tables 1 and 2), treatment with tirzepatide was related to an improvement in the lipid profile, with major decreases in triglycerides (Table 4) that cannot be fully accounted for by reductions in weight alone [77]
Weight regain after stopping is documented and common
Tirzepatide builds on this foundation by simultaneously activating both GLP-1 and GIP receptors, potentially offering greater weight reduction for patients who plateau or seek enhanced results
While chronic inflammatory response syndrome (CIRS) represents a well-described subset characterized by specific biomarker patterns and immune dysregulation, not all patients with mycotoxin exposure meet criteria for CIRS
A two-day (48-hour) advance creates a 120-hour interval from your previous dose, still safely above the critical 72-hour minimum and unlikely to cause harm as a one-time occurrence
